Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageWe are a global provider of medical devices and human tissue cryopreservation services largely used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. We develop, manufacture, and market vascular devices to address the needs of vascular surgeons and, to a lesser degree, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Our diversified portfolio of devices consists of brand name products that are used in arteries and veins and are well known to vascular surgeons.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Jun 2026 · $70.4MThe company’s own SEC segment disclosure.
- United States$38.3M54%
- Other Countries$18.5M26%
- Germany$5.3M8%
- Canada$4.6M6%
- United Kingdom$3.7M5%
LeMaitre Vascular, Inc. (LMAT) reported revenue of $67M in Q1 2026 (quarter ended Mar 31, 2026), up 11% from the same quarter a year earlier. That came with a gross margin of 73% and net income of $16M (24% of revenue). For the full year FY2025, revenue was $250M (+14% year on year) and net income $58M. Its largest region in Jun 2026 was United States at $38M, 54% of the disclosed total, well ahead of Other Countries at 26%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Medical Instruments & Supplies
Ranks #7 of 19 by Smart Score